Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLS-5700
- Development stage
- Phase 1
- Lead developer
- Inovio Pharmaceuticals
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
GLS-5700 is a synthetic DNA plasmid vaccine developed to prevent Zika virus infection. Co-developed by Inovio Pharmaceuticals and GeneOne Life Science, the vaccine encodes the premembrane-membrane (prM) and envelope (E) proteins of the Zika virus. It is administered via intradermal injection followed by electroporation using Inovio's proprietary CELLECTRA device, which facilitates the entry of the DNA plasmids into host cells to induce both humoral and cellular immune responses. GLS-5700 was the first Zika vaccine to enter human clinical trials, advancing rapidly from preclinical development to Phase 1 studies in response to the 2015-2016 Zika public health emergency.
- Other names
- Zika DNA vaccine
02
Targets
ZIKV E (Zika virus envelope protein)prM (Zika virus precursor membrane protein)
Beyond the preview
Go deeper on GLS-5700.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLS-5700.